



2020

Human embryonic stem cells differentiation into oligodendrocyte lineage cells

Paria Pooyan^{1,2,3}

¹Department of Molecular Systems Biology, Cell Science Research Center, Royan Institute for Stem Cell Biology and Technology, ACECR, Tehran, Iran, ²Department of Stem Cells and Developmental Biology, Cell Science Research Center, Royan Institute for Stem Cell Biology and Technology, ACECR, Tehran, Iran, ³Department of Brain and Cognitive Science, Cell Science Research Center, Royan Institute for Stem Cell Biology and Technology, ACECR, Tehran, Iran



dx.doi.org/10.17504/protocols.io.bddni25e



🔔 Paria Pooyan 🕢



ABSTRACT

Oligodendrocyte (OL) lineage cell generation from human embryonic stem cell line Royan H6 (RH6) started by dual inhibition of SMAD signaling. Therefore, within eight days, adherent NANOG+RH6 cells (B) differentiated into SOX1+ neural stem cells (C). Next, the embryonic ventral spinal cord environment (pMN domain) was mimicked by the application of two morphogens, RA and SAG and the OLIG2⁺ neural progenitor cells were generated on day 12 (D) of differentiation. Further, oligodendrocyte progenitor cell commitment was achieved on day 20, when the pre-oligodendrocyte progenitor cell (pre-OPC) aggregates were positively stained by NKX2.2+ (E). From day 20 to day 80, supportive reagents for pre-OPCs maturation into PDGFRA+ OPCs (F), and their further expansion and maturation toward oligodendrocyte producing OPCs were added to the culture medium. Finally, on day 80 the growth-factors were withdrawn from the culture medium and OPCs were differentiated into MBP+ OLs (G).

References:

- Baharvand H, Ashtiani SK, Taee A, Massumi M, Valojerdi MR, Yazdi PE, et al. Generation of new human embryonic stem cell lines with diploid and triploid karyotypes. Dev Growth Differ. 2006;48:117-28.
- Douvaras P, Wang J, Zimmer M, Hanchuk S, O'Bara MA, Sadiq S, et al. Efficient generation of myelinating oligodendrocytes from primary progressive multiple sclerosis patients by induced pluripotent stem cells. Stem Cell Reports [Internet]. The Authors; 2014;3:250-9. Available from: http://dx.doi.org/10.1016/j.stemcr.2014.06.012
- Douvaras P, Fossati V. Generation and isolation of oligodendrocyte progenitor cells from human pluripotent stem cells. Nat Protoc [Internet]. 2015;10:1143-54. Available from: http://dx.doi.org/10.1038/nprot.2015.075
- Piao J, Major T, Auyeung G, Policarpio E, Menon J, Droms L, et al. Human embryonic stem cell-derived oligodendrocyte progenitors remyelinate the brain and rescue behavioral deficits following radiation. Cell Stem Cell [Internet]. Elsevier Inc.; 2015;16:198-210. Available from: http://dx.doi.org/10.1016/j.stem.2015.01.004

MATERIALS TEXT

Media	Components	Provider	Final
			Conc.
NI medium	DMEM/F12	Life Technologies	
	Knock-Out Serum*	Life Technologies	5%
	MEM Non-Essential Amino Acids (100X)	Life Technologies	1X
	GlutaMAX-I (100X)	Life Technologies	1X
	Penicillin-Streptomycin (100X)	Life Technologies	1X
	2-Mercaptoethanol (1000X)	Life Technologies	1X
	Insulin-Transferrin-Selenium (100X)	Life Technologies	1X
	N-2 Supplement (100X)	Life Technologies	1X
	SB431542	Stemgent	10 μΜ

protocols.io 03/16/2020

Citation: Paria Pooyan (03/16/2020). Human embryonic stem cells differentiation into oligodendrocyte lineage cells. https://dx.doi.org/10.17504/protocols.io.bddni25e

	LDN193189	Stemgent	250 nM
	All Trans-Retinoic Acid	Sigma	100 nM
N2 medium	DMEM/F12	Life Technologies	
	MEM Non-Essential Amino Acids (100X)	Life Technologies	1X
	GlutaMAX-I (100X)	Life Technologies	1X
	Penicillin-Streptomycin (100X)	Life Technologies	1X
	2-Mercaptoethanol (1000X)	Life Technologies	1X
	Insulin-Transferrin-Selenium (100X)	Life Technologies	1X
	N-2 Supplement (100X)	Life Technologies	1X
	All Trans-Retinoic Acid	Sigma	100 nM
	Agonist of Sonic Hedgehog (SAG)	Stemgent	1 µM
N2B27 medium	DMEM/F12	Life Technologies	
	MEM Non-Essential Amino Acids (100X)	Life Technologies	1X
	GlutaMAX-I (100X)	Life Technologies	1X
	Penicillin-Streptomycin (100X)	Life Technologies	1X
	2-Mercaptoethanol (1000X)	Life Technologies	1X
	Insulin-Transferrin-Selenium (100X)	Life Technologies	1X
	N-2 Supplement (100X)	Life Technologies	1X
	B-27 Supplement without Vitamin A (50X)	Life Technologies	1X
	All Trans-Retinoic Acid	Sigma	100 nM
	SAG	Stemgent	1 μΜ
PDGF medium	DMEM/F12	Life Technologies	
	MEM Non-Essential Amino Acids (100X)	Life Technologies	1X
	GlutaMAX-I (100X)	Life Technologies	1X
	Penicillin-Streptomycin (100X)	Life Technologies	1X
	2-Mercaptoethanol (1000X)	Life Technologies	1X
	N-2 Supplement (100X)	Life Technologies	1X
	B-27 Supplement without Vitamin A (50X)	Life Technologies	1X
	Insulin	Sigma	25 µg/ml
	PDGF-AA	Sigma	10 ng/ml
	HGF	Sigma	5 ng/ml
	IGF-1	Sigma	10 ng/ml
	NT3	Royan Biotech	10 ng/ml
	T3	Sigma	60 ng/ml
	Biotin	Sigma	100ng/ml
	cAMP	Sigma	1µM
Glial medium	DMEM/F12	Life Technologies	
	MEM Non-Essential Amino Acids (100X)	Life Technologies	1X
	GlutaMAX-I (100X)	Life Technologies	1X
	Penicillin-Streptomycin (100X)	Life Technologies	1X
	2-Mercaptoethanol (1000X)	Life Technologies	1X
	N-2 Supplement (100X)	Life Technologies	1X
	B-27 Supplement without Vitamin A (50X)	Life Technologies	1X
	Insulin	Sigma	25 μg/ml
	HEPES	Sigma	10 mM
	Т3	Sigma	60 ng/ml
	Biotin	Sigma	100ng/ml
	cAMP	Sigma	1µM
	AA	Sigma	20 μg/ml

^{*} From day four of differentiation, Knock-Out serum was gradually replaced by N-2 supplement (25%, 50%, 75%) as described previously.

- $1 ext{6} imes 10^6$ RH6 cells were plated on Engelbreth-Holm-Swarm mouse sarcoma ECM (sigma) coated 6cm cell culture plates on day -1.
- 2 On day 0, the FFC medium (containing 20% KSR and 100 ng/ml bFGF) was replaced by 4 ml NI medium. NI medium was refreshed every day.
- 3 On day 8, the NI medium was replaced with N2 medium and the medium was refreshed every day.
- 4 From day 4, 5% KSR was gradually withdrawn from the NI medium. Respectively, 3.75%, 2.5%, 1.25% and 0% KSR was applied in the NI medium on day 4, 5, 6 and 7.
- On day 12, cells' attachment was loosened by PBS for 10 min. Then PBS was replaced with the N2B27 medium and cells were detached by braking their layer via the tip of the p1000 pipette. The cell clumps were pipetted gently with a p1000 pipette, for 5 times.
- Detached cells were transferred into the 6 cm untreated plates to form aggregates and from day 14, two-thirds of the N2B27 medium was refreshed every day. The debris and dead cells were removed through the medium refreshment. Meanwhile, the aggregates that stuck to each other were broken apart by gentle pipetting (with the p1000 pipette).
- 7 On day 20, two-thirds of the N2B27 medium was replaced with PDGF medium. Two-thirds of the PDGF medium was refreshed every day until day 80.
- On day 29, new 6 cm culture dishes were coated for overnight by 50 μ g/ml poly-l-ornithine in dH20, at 37 °C. Next, they were coated by 20 μ g/ml laminin in PBS for 12 h at 37 °C.
- On day 30, golden or brown aggregates (with a dark center) were plated on poly-l-ornithine/laminin coated dishes, with a p200 pipette (50 spheres per each 6 cm culture plate). The daily refreshment of the two-third of the PDGF medium was performed gently until day80.
- 10 FFirst on day 65 and then on day 75, cells and aggregates were re-plated on newly poly-l-ornithine/laminin coated dishes to achieve a more homogenous OPC population on day 80. PBS and the p200 pipette were used for detachment and replacement.
- On day 80, the PDGF medium was replaced by the Glial medium. Two-thirds of the medium was refreshed every two to three days, until day 120.

This is an open access protocol distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited